GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sierra Oncology Inc (NAS:SRRA) » Definitions » Price-to-Tangible-Book

Sierra Oncology (Sierra Oncology) Price-to-Tangible-Book : 5.00 (As of Apr. 27, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Sierra Oncology Price-to-Tangible-Book?

As of today (2024-04-27), Sierra Oncology's share price is $54.99. Sierra Oncology's Tangible Book per Share of Mar. 2022 for the quarter that ended in Mar. 2022 was $10.99. Hence, Sierra Oncology's Price to Tangible Book Ratio of today is 5.00.

The historical rank and industry rank for Sierra Oncology's Price-to-Tangible-Book or its related term are showing as below:

SRRA' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.3   Med: 1.18   Max: 5
Current: 5

During the past 9 years, Sierra Oncology's highest Price to Tangible Book Ratio was 5.00. The lowest was 0.30. And the median was 1.18.

SRRA's Price-to-Tangible-Book is not ranked
in the Biotechnology industry.
Industry Median: 2.65 vs SRRA: 5.00

A closely related ratio is called PB Ratio. As of today, Sierra Oncology's share price is $54.99. Sierra Oncology's Book Value per Sharefor the quarter that ended in Mar. 2022 was $10.99. Hence, Sierra Oncology's P/B Ratio of today is 5.00.


Sierra Oncology Price-to-Tangible-Book Historical Data

The historical data trend for Sierra Oncology's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sierra Oncology Price-to-Tangible-Book Chart

Sierra Oncology Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Price-to-Tangible-Book
Get a 7-Day Free Trial Premium Member Only 2.06 1.04 0.30 1.82 3.53

Sierra Oncology Quarterly Data
Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22
Price-to-Tangible-Book Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.10 2.86 3.34 3.53 2.92

Competitive Comparison of Sierra Oncology's Price-to-Tangible-Book

For the Biotechnology subindustry, Sierra Oncology's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sierra Oncology's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sierra Oncology's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Sierra Oncology's Price-to-Tangible-Book falls into.



Sierra Oncology Price-to-Tangible-Book Calculation

Sierra Oncology's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book=Share Price/Tangible Book per Share (Q: Mar. 2022 )
=54.99/10.992
=5.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.


Sierra Oncology Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Sierra Oncology's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.


Sierra Oncology (Sierra Oncology) Business Description

Traded in Other Exchanges
N/A
Address
1820 Gateway Drive, Suite 110, San Mateo, USA, 94404
Sierra Oncology Inc is a clinical-stage drug development company. It focuses on the research, development, and commercialization of DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer in the United States and internationally. The company's lead drug candidate is SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1, which is in Phase 1 clinical trial to treat patients with advanced cancer. In addition, it also engaged in developing SRA141, an orally bioavailable small molecule inhibitor of the cell division cycle 7 kinase that is in the preclinical development stage.
Executives
Vivo Opportunity Fund Holdings, L.p. director, 10 percent owner 192 LYTTON AVENUE, PALO ALTO CA 94301
William D. Turner officer: Chief Reg & Tech Ops Officer C/O SIERRA ONCOLOGY, INC. 1820 GATEWAY DRIVE, SUITE 110 SAN MATEO CA 94404
Mary Christina Thomson officer: General Counsel C/O SIERRA ONCOLOGY, INC. 1820 GATEWAY DRIVE, SUITE 110 SAN MATEO CA 94404
Joshua Richardson director, 10 percent owner C/O LONGITUDE CAPITAL 2740 SAND HILL ROAD, 2ND FLOOR MENLO PARK CA 94025
Longitude Capital Partners Iii, Llc 10 percent owner 800 EL CAMINO, SUITE 220, MENLO PARK CA 94025
Longitude Prime Fund, L.p. 10 percent owner 2740 SAND HILL ROAD, 2ND FLOOR, MENLO PARK CA 94025
Longitude Prime Partners, Llc 10 percent owner 2740 SAND HILL ROAD, 2ND FLOOR, MENLO PARK CA 94025
Gaurav Aggarwal director, 10 percent owner C/O PANORAMA CAPITAL, 2440 SAND HILL ROAD, SUITE 302, MENLO PARK CA 94025
Llp Abingworth 10 percent owner 38 JERMYN STREET, LONDON X0 SW1Y 6DN
Vivo Opportunity Fund, L.p. 10 percent owner 192 LYTTON AVENUE, PALO ALTO CA 94301
Andrew Sinclair director C/O SOLENO THERAPEUTICS INC., 1235 RADIO ROAD, SUITE 110, REDWOOD CITY CA 94065
Orbimed Genesis Gp Llc director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Craig A Collard director C/O CORNERSTONE THERAPEUTICS INC., 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518
Georgia Erbez director 6300 DUMBARTON CIRCLE, FREMONT CA 94555
Christy J. Oliger director 85 WELLS AVENUE, SUITE 210, NEWTON MA 02459

Sierra Oncology (Sierra Oncology) Headlines

From GuruFocus

New Leaf Venture Partners, L.L.C.'s Top 5 Sells of the 4th Quarter

By GuruFocus Research GuruFocus Editor 02-07-2023